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Summary The mechanisms that cause chemoresistance of gastric cancer have yet to be
elucidated. Taxanes and promising agents that were recently approved for treatment of
advanced or recurrent gastric cancer. Mutations of beta-tubulin, which is a target of taxianes,
have been shown to confer chemoresistance against these agents. The aim of the present study
is to investigate the presence of mutations of the beta-tubulin in gastric cancer tissues. Sixty-
six patients with advanced stage III or IV gastric cancer patients enrolled in this study. Paired
samples of gastric cancer tissue and normal mucosa were obtained by endoscopy. The
guanosine 5'-triphosphate (GTP)-binding site in exon 4 of the beta-tubulin gene was examined
by polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP)
analysis, followed by sequencing of the products with abnormally shifted bands. SSCP analysis
showed abnormal bands upstream of the GTP-binding site in 7 of the 66 patients, but sequence
analysis found no nucleotide substitutions in these patients. Three variant bands were also
detected down stream of the the GTP-binding site, but the sequences of the 3 products
corresponded to those of two independent pseudogenes. Thus, none of the tumor samples
showed mutation of the beta-tubulin exon 4 GTP-binding site. In conclusion, these findings
suggest that mutations of the beta-tubulin gene are rare and are unlikely to be an important
cause of taxane resistance to taxians.
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Introduction
Gastric cancer is one of the most common and lethal
malignancies in Japan. Although the incidence and mortality
rate of gastric cancer located outside the cardia have been
decreasing over the last few decades, many patients still
have advanced disease at diagnosis and not indicated for
curative surgery. Chemotherapy with a single agent or a
combination of anticancer drugs has generally been used
treat advanced or recurrent gastric cancer, but the response
has not been adequate. Taxanes including paclitaxicel and
docetaxel have recently been approved for several cancers,
including gastric cancer, and have shown promise for the
management of advanced or recurrent gastric cancer [1, 2].
Taxanes bind to beta-tubulin, which is one of the major
components of microtubules [3], and exert a growth-inhibitory
effect through the stabilization of microtubules, that causes
arrest of tumor cells in the G2-M phase of the cell cycle [4].
The beta-tubulin gene is located in chromosome region
6p21.3 and has four exons [5]. The protein is composed
sequence of 445 amino acids. Although the mechanism of
taxane resistance has not been clearly demonstrated for
gastric cancer, Schibler has reported that beta-tubulin gene
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mutations in Chinese hamster ovary (CHO) cells could
select for resistance to and/or dependence on paclitaxel [6].
In addition, recently point mutations of the beta-tubulin gene,
predominantly in exon 4, have recently been reported to show
an association with resistance to paclitaxicel [7–9]. Exon 4
encodes guanosine 5′-triphosphate (GTP)-binding sites, and
thus it is speculated that mutations of this region may prevent
GTP from promoting microtubule assembly, so that taxane-
induced polymerization may not occur [10, 11]. Previous
reports about beta-tubulin mutations in gastric cancer have
been relatively uncommon. Urano analyzed 50 gastric tumors
and found no mutations of the exon 4 GTP-binding site [12],
more than half of the tumor samples were obtained from
patients with early stage I or II diseases, while chemotherapy
is usually given to patients with advanced disease. If beta-
tubulin mutations are an acquired change, it is reasonable to
expect that such mutations would be more common in
advanced tumors. According, the present study examined
whether or not exon 4 mutations, of the beta-tubulin gene
existed in advanced stage III or IV gastric cancer.
Materials and Methods
Patients and DNA extraction
A total of 66 patients with stage III or IV gastric cancer
were enrolled in this study. Each patient underwent endo-
scopy on admission and samples of tumor tissue and normal
gastric mucosa were obtained by endoscopic biopsy. Histo-
logic examination of selected material showed that the
tumor samples contained 40% to 90% tumor cells. The
specimens were snap frozen in liquid nitrogen and stored at
−70°C until use. Genomic DNA was extracted directly from
the frozen tissues by incubation in 10 mmol/L Tris (pH 8.1),
50 mmol/L KCL, SDS, EDTA, and 1 mg/mL proteinase K.
Then each DNA sample was precipitated with ethanol,
dried, in vacuo, and resuspended in 8 mmol/L NaOH. All
specimens were collected after written informed consent
was obtained from the patients and Ethics Committee of
Fujita Health University School of Medicine approved the
study protocol.
Polymerase chain reaction
The primer sets were designed to amplify specific regions
of exon 4 of the beta-tubulin gene that code for the GTP-
binding site (Fig. 1 and Table 1). To confirm that the amplicon
was not from a pseudogene, the entire length of exon 4 was
amplified first and then divided into two regions, that were
amplified by using nested polymerase chain reaction (PCR).
The PCR mixture (25 µL) contained 80–100 ng of extracted
DNA, 5 pmol of the forward and reverse primers, 200 µmol
of dNTP, 0.5 units of Taq polymerase, and 2.5 µL of standard
NH3 buffer with 1.5 µL of 1.5 mmol MgCl2. (Toyobo, Tokyo
Japan). PCR was commenced with incubation at 95°C for
7 min, followed by 35 cycles of 95°C for 30 s, 52 or 57°C
depending on the primer for 40 s, and 72°C for 40 s. Final
extension was done at 72°C for 7 mins. For amplification of
the entire exon 4, the extension time was prolonged for
1.5 min.
SSCP analysis
SSCP analysis was performed by using a Gene Gel Exel
12.5/24 Kit (Amersham Bioscience, NJ). After electrophoresis
was done for 80 min at 18°C and 600 V, the bands were
visualized by silver staining.
Sequencing analysis
Samples with abnormally shifted bands on SSCP analysis
were subjected to direct DNA sequencing by using a Big
Dye Terminator version 3 Direct Cycle Sequencing Kit
(Applied Biosystems, Tokyo Japan) with electrophoresis of
the products in an automatic DNA sequencer (ABI PRISM
310TM Genetic Analyzer, Applied Biosystems, Tokyo,
Japan). The sequence data thus obtained were compared
with the sequence of class I beta-tubulin in the GenBank
data base (J00314).
Fig. 1.  Diagram of the beta-tubulin gene showing its exons,
with oligonucleotides used for PCR amplification and
sequencing (Table 2) indicated by arrows. The GTP-
binding site is shown above the protein.
Table 1. Beta-tubulin primers and annealing temperatures for PCR
Name Position Sequence
Annealing 
Temperature (°C)
BT1F Forward tagcttttctcctgactggc 58
BT1R Reverse aatcggcagaatgagttgac 58
BT2F Forward agagagctgtgactgcctg 52
BT2R Reverse aaggtattcatgatgcga 52
BT3F Forward cgcatcatgaataccttcag 54
BT3R Reverse gtgagagctcgatactgctg 52
BT1: The entire exon 4. BT2: Upstream of the GTP- binding site.
BT3: Downstream of the GTP-binding site.T. Tahara et al.
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Results
Patient characteristics
The clinicopathological characteristics of the 66 patients
are listed in Table 2. Among the 66 patients, 56 had received
no prior treatment, 2 had been treated with TS-1, and 7
had been treated with TS-1 plus cisplatin as first-line
chemotherapy. Only one tumor biopsy specimen was a taken
after paclitxel treatment.
Mutation analysis of the exon 4 GTP-binding site
SSCP analysis showed abnormal bands upstream of the
GTP-binding site in 7 out of 66 patients in the (Fig. 2a, b).
However, sequence analysis found no nucleotide substitutions
in any of the cases. Three variant bands were detected down
stream of the GTP-binding site (Fig. 2c, d). The sequence of
one of these 3 products showed 8 nucleotide substitutions
compared with that of class I beta-tubulin in the GenBank
data base (J00314), but these corresponded to the sequence
of a pseudogene (NT007995; Fig. 3a). The other two
products had 4 nucleotide substitutions, but these matched
the sequence of another pseudogene (NT086688; Fig. 3b,
3c). Thus, none of the tumors had any mutations at the GTP-
binding site of exon 4 in the beta-tubulin gene.
Discussion
The success of anti cancer chemotherapy is limited by the
development of tumor resistance. As is frequently observed
with other chemotherapy agents, some of the patients who
initially respond to taxanes later undergo relapse. Furthermore,
some tumors are entirely resistant to taxanes even during
initial treatment. Paclitaxel is reported to be effective for
gastric cancer, with response rates ranging from 20% to 28%
in single-agent phase II studies [1, 2], but more than half of
all patients will not show any response to paclitaxel. Thus,
understanding the mechanisms of resistance to taxanes is
important for developing new approaches.
The rationale for assessing the relationship between beta-
tubulin gene mutations and paclitaxel resistance is based on
the studies of Giannakakou et al. [7] and Gonzarez-Garay et
al. [8], who found beta-tubulin gene mutations in ovarian
cancer cell lines and hamster cells, respectively. Subsequently,
Monzo  et al. [ 9] reported beta-tublin gene mutations,
predominantly at exon 4, in paclitaxel-resistant tumors from
patients with advanced non-small cell lung cancer and
Table 2. Clinicopathologic characteristics of patients
Variable (n)
Mean age (range/years) 67.4 (29–90)
Sex (Male : Female) 46:20:00
Histologic subtype
Intestinal 37
Diffuse 29
Stage
IIIA 23
IIIB 19
IV 24
Fig. 2.  Single-strand conformational polymorphism (SSCP) analysis of the exon 4 GTP-binding site. Arrows indicate the abnormally
shifted bands. a, b; Seven of 66 patients had bands upstream of the GTP-binding site (BT2), 1-7. c, d; Three patients had
downstream bands (BT3), A, B and C; Fig. 1, Table 2.Beta-Tubulin Gene Mutation in Gastric Cancer
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proposed that such mutations could have a possible role in
paclitaxel resistance by this cancer. However, in agreement
with another recent report about gastric cancer [12], we did
not find any mutations of the exon 4 GTP-binding site in
advanced stage III and IV gastric cancer. Although we spec-
ulated that beta-tubulin gene mutations may be acquired
changes that would occur more often in advanced tumors,
investigation of 66 all advanced stage III or IV gastric
cancers, found no such mutations. The sequences of 7 prod-
ucts with abnormally bands upstream of the GTP-binding
site did not show any mutations, while the sequences of
three downstream products corresponded to those of two
previously described independent pseudogenes. In agreement
with our results, similar finding have recently been obtained
for several other tumors, namely lung cancer [13], breast
cancer [14, 15], and ovarian cancer [16, 17]. Taken together,
these investigations indicate that beta-tubulin gene mutations
are not an important mechanism of paclitaxel resistance. To
Fig. 3.  Sequence analysis of polymerase chain reaction products. a; Case A. b; Case B. c; Case C. (From Fig. 2). The sequence of case
A showed 8 nucleotide substitutions compared with the class I beta-tubulin sequence reported in the GenBank data base
(J00314), but these all corresponded to the sequence of a pseudogene (NT08688). The sequences of cases B and C had same 4
nucleotide substitutions, but these corresponded to the sequence of another pseudogene (NT007995).T. Tahara et al.
J. Clin. Biochem. Nutr.
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explain the findings of Monzo et al. [9], which have not been
reproduced by other investigations including the present
study, Kelley et al. suggested that the primers used in the
early study did not discriminate beta tubulin from its
pseudogenes [13]. Also, the first reports of beta-tubulin gene
mutations were based on investigation of hamster cells [8]
and ovarian cancer cell lines [7] after selection by exposure
to paclitaxel, so direct extrapolation of these findings to
human tumors is difficult.
In the present study, we analyzed beta-tubulin gene
mutations in gastric cancer tissue, obtained by endoscopic
biopsiy of the tumor surface. Therefore, it should be noted that
the results may not reflect the characteristics of deeper part of
the tumor. However, in patients who cannot undergo surgery,
we have to collect information about chemoresistance from
samples obtained by endoscopic biopsy. Thus, the problem
which now confronts us is how to obtain information from
such tiny superficial tumor samples. In contexts, beta-tubulin
may not be a good marker for predicting chemoresistance to
taxanes in patients with gastric cancer. For example, analysis
of single nucleotide polymorphism may be a useful marker
for expecting chemotherapeutic efficacy or toxity [18].
In conclusion, our findings indicate that beta-tubulin exon
4 is very well conserved even in advanced stage III or IV
gastric cancer, making it very unlikely that variations in the
response to treatment with taxanes are caused by mutations
of this gene. Further investigation of alternative mechanisms
of taxane resistance is warranted, including P-glycoprotein
overexpression [18,  19], differential beta-tubulin isotype
expression [18, 20, 21], and deregulation of apoptosis [18,
22–24]. Such studies are necessary to predict the response of
individual patients to this agent.
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